Correspondence 0001493152-24-052621 from ORAGENICS INC (OGEN)
ORAGENICS INC
Date: Dec. 31, 2024 · CIK: 0001174940 · Accession: 0001493152-24-052621
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283927
Referenced dates: December 30, 2024
Letter
Via Edgar United States Securities and Exchange Commission Re: Oragenics, Inc. Registration Statement on Form S-1 Filed December 18, 2024 File No. 333-283927
Dear Mr. McCann:
Set forth below is the response of Oragenics, Inc. (the “Company”) to the Staff of the Division of Corporation Finance’s comment letter dated December 30, 2024, with respect to the Company’s Registration Statement on Form S-3 (333-283927) filed on December 18, 2024. For your convenience, the Staff’s comments are set forth in bold and followed by the Company’s response.
Comments
Registration Statement on Form S-1
Cover Page
1. Please revise the header information to clarify that the Units may contain pre-funded warrants. Please also include the placement agent warrants in the header.
Response: The Company has amended the header information in its Form S-1 to clarify the Units may contain Pre-Funded Warrants and to include the Placement Agent Warrants.
Securities and Exchange Commission
December 31, 2024
Page
Should you have any questions or clarifications of the matters raised in this letter please contact the undersigned at (813) 229-7600.
Sincerely,
/s/Julio
C. Esquivel
Show Raw Text
CORRESP
1
filename1.htm
Bank
of America Plaza
101
East Kennedy Boulevard
Suite
2800
Tampa,
Florida 33602
813.229.7600
813.229.1660
fax
julio
c. esquivel
(813)
227-2325
jesquivel@shumaker.com
December
31, 2024
Via
Edgar
Joseph
McCann and Chris Edwards, Division of Corporation Finance
United
States Securities and Exchange Commission
100
F Street
Washington,
DC 20549
Re:
Oragenics,
Inc.
Registration
Statement on Form S-1
Filed
December 18, 2024
File
No. 333-283927
Dear
Mr. McCann:
Set
forth below is the response of Oragenics, Inc. (the “Company”) to the Staff of the Division of Corporation Finance’s
comment letter dated December 30, 2024, with respect to the Company’s Registration Statement on Form S-3 (333-283927) filed on
December 18, 2024. For your convenience, the Staff’s comments are set forth in bold and followed by the Company’s response.
Comments
Registration
Statement on Form S-1
Cover
Page
1. Please
revise the header information to clarify that the Units may contain pre-funded warrants.
Please also include the placement agent warrants in the header.
Response: The
Company has amended the header information in its Form S-1 to clarify the Units may contain
Pre-Funded Warrants and to include the Placement Agent Warrants.
Securities
and Exchange Commission
December
31, 2024
Page
2
Should
you have any questions or clarifications of the matters raised in this letter please contact the undersigned at (813) 229-7600.
Sincerely,
/s/Julio
C. Esquivel
Julio
C. Esquivel
c:
Janet Huffman, Chief Financial Officer, Oragenics, Inc.